Lessons From SADHART, ENRICHD, and Other Trials
The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Depression is highly prevalent in patients with cardiovascular disease and is independently associated with a poor prognosis when present. A very important aspect of continued therapeutic advances in this field will be the ability to show a convincing connection between the treatment of depression in patients with heart disease and a reduction in morbidity and mortality associated with the co-occurrence of these conditions. The recent SADHART (Sertraline AntiDepressant Heart Attack Trial) investigation demonstrated that sertraline is safe and efficacious in depressed patients with ischemic heart disease but was underpowered to detect a mortality difference between sertraline and placebo. The ENRICHD (ENhancing Recovery in Coronary Heart Disease) trial showed that cognitive-behavioral therapy is effective for treating depression but had no impact on cardiovascular morbidity or mortality. There are a number of methodologic complexities associated with research regarding depression and cardiovascular disease, including difficulties in the definition and measurement of depression, complexities in the conduction of large-scale trials, ethical considerations surrounding the use of placebo, and interpretation of trial results. In addition, the lack of certainty regarding the pathophysiologic link between depression and cardiovascular disease means that there is a lack of pharmacotherapy targeted specifically at the dysregulated physiology that might explain the increased morbidity and mortality seen when these two conditions occur together. BDI = Beck Depression Inventory; CAD = coronary artery disease; CBT = cognitive behavioral therapy; CGI-I = Clinical Global Impression Improvement; CVD = cardiovascular disease; ECG = electrocardiogram; ENRICHD = Enhancing Recovery in Coronary Heart Disease; HAM-D = Hamilton Depression; HR = hazard ratio; HRV = heart rate variability; HRSD = Hamilton Rating Scale for Depression; MI = myocardial infarction; MIND-IT = Myocardial Infarction and Depression Intervention Trial; NHLBI = National Heart Lung and Blood Institute; SADHART = Sertraline Anti-Depressant Heart Attack Randomized Trial; SSRI = selective serotonin reuptake inhibitor.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rozanski, A., Blumenthal, J. A., & Kaplan, J. (1999) · Circulation · doi:10.1161/01.cir.99.16.2192 · Cited by 2,846
The Relationship of Depression to Cardiovascular Disease: Epidemiology, Biology, and Treatment
Musselman, D. L., Evans, D. L., & Nemeroff, C. B. (1998) · Archives of General Psychiatry · doi:10.1001/archpsyc.55.7.580 · Cited by 1,532
Sertraline treatment of major depression in patients with acute MI or unstable angina
Glassman, A. H. (2002) · JAMA · doi:10.1001/jama.288.6.701 · Cited by 1,414
Placebo Response in Studies of Major Depression: Variable, Substantial, and Growing
Walsh, B. T., Seidman, S. N., Sysko, R., & Gould, M. (2002) · JAMA · doi:10.1001/jama.287.14.1840 · Cited by 1,109 · cited 3×
“Because placebo response rates are quite high in most antidepressant efficacy trials (21), it can be difficult to sort out the precise impact of a particular intervention on depressive symptoms.”
BackgroundJiang, W., Alexander, J., Christopher, E., Kuchibhatla, M., Gaulden, L. H., Cuffe, M. S., Blazing, M. A., Davenport, C., Califf, R. M., Krishnan, R. R., et al. (2001) · Archives of Internal Medicine · doi:10.1001/archinte.161.15.1849 · Cited by 934 · cited 1×
“Many patients with cardiovascular disease will experience mild depression that is not easy to differentiate from a normal grief response to the diagnosis of a significant illness, while many others will experience moderate to severe depression (6).”
BackgroundSelf-citationCytokine Production and Treatment Response in Major Depressive Disorder
Lanquillon, S. (2000) · Neuropsychopharmacology · doi:10.1016/s0893-133x(99)00134-7 · Cited by 735 · cited 1×
“(15) showed that responders to treatment demonstrated decreased inflammation, whereas nonresponders showed no change.”
BackgroundMaes, M., Meltzer, H. Y., Bosmans, E., Bergmans, R., Vandoolaeghe, E., Ranjan, R., & Desnyder, R. (1995) · Journal of Affective Disorders · doi:10.1016/0165-0327(95)00028-l · Cited by 622 · cited 1×
“reported that treatment with selective serotonin reuptake inhibitors (SSRIs) had no effect on acute-phase or inflammatory markers (13); however, Mikova et al.”
BackgroundFrasure-Smith, N., Lespérance, F., Prince, R. H., Verrier, P., Garber, R. A., Juneau, M., Wolfson, C., & Bourassa, M. G. (1997) · The Lancet · doi:10.1016/s0140-6736(97)02142-9 · Cited by 461
Cited by
Lagraauw, H. M., Kuiper, J., & Bot, I. (2015) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2015.08.007 · Cited by 268
The epidemiology of excess mortality in people with mental illness
Lawrence, D., Kisely, S., & Pais, J. (2010) · The Canadian Journal of Psychiatry · doi:10.1177/070674371005501202 · Cited by 258
Goldstein, C. M., Gathright, E. C., & Garcia, S. (2017) · Patient Preference and Adherence · doi:10.2147/ppa.s127277 · Cited by 138
“As the pathophysiological link between depression and CVD remains unclear, there is a similar lack in pharmacotherapy that targets the dysregulated physiology that might help explain the increased morbidity and mortality in patients with both CVD and depression.(82) Therefore, future pharmaceutical and behavioral rese…”
Sheps, D. S., & Rozanski, A. (2005) · Psychosomatic Medicine · doi:10.1097/01.psy.0000164251.27403.d9 · Cited by 23
“One article examines the relative safety of using selective serotonin reuptake inhibitors (SSRIs) versus tricyclic antidepressants in patients with CAD (17); one evaluates nonpharmacologic forms of treating depression in patients with CAD (18), and one reviews lessons learned from the recently conducted clinical trial…”
Background
Metadata
- Authors
- Joynt, K. E., & OʼConnor, C. M.
- Venue
- Psychosomatic Medicine
- Published
- 2005-05
- Volume
- 67
- Pages
- S63-S66
- ISSN
- 0033-3174 (ISSN-L)
- OpenAlex
- W2087725126
- Cited by
- 82
- References
- 9
- FWCI
- 4.24
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.